CD274 and neoplasm: The involvement of anti-PD-L1 mAbs in the increase of sPD-L1, regardless of tumor histotypes or treatment schedules, was enforced by the comprehensive analysis performed on all patients treated with anti-PD-L1 mAbs, alone or in combination.